Coya Therapeutics’ (COYA) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a research note published on Monday,Benzinga reports. D. Boral Capital currently has a $15.00 target price on the stock.

Other research analysts have also recently issued research reports about the company. HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Coya Therapeutics in a research report on Monday, November 11th. Chardan Capital reaffirmed a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a research note on Thursday, February 6th.

Coya Therapeutics Trading Down 4.9 %

NASDAQ COYA opened at $6.54 on Monday. The stock has a market capitalization of $109.26 million, a price-to-earnings ratio of -10.06 and a beta of 0.31. The business’s 50 day moving average is $6.22 and its two-hundred day moving average is $6.46. Coya Therapeutics has a 12-month low of $4.75 and a 12-month high of $10.69.

Hedge Funds Weigh In On Coya Therapeutics

Hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC boosted its position in Coya Therapeutics by 3.3% during the third quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock worth $918,000 after purchasing an additional 4,485 shares in the last quarter. Newbridge Financial Services Group Inc. purchased a new stake in shares of Coya Therapeutics in the 4th quarter worth about $401,000. CM Management LLC grew its stake in Coya Therapeutics by 11.1% in the 4th quarter. CM Management LLC now owns 160,000 shares of the company’s stock valued at $917,000 after acquiring an additional 15,941 shares during the last quarter. Jane Street Group LLC acquired a new stake in Coya Therapeutics in the 4th quarter valued at about $74,000. Finally, Northern Trust Corp increased its holdings in Coya Therapeutics by 12.2% during the 4th quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock valued at $164,000 after acquiring an additional 3,099 shares in the last quarter. 39.75% of the stock is owned by hedge funds and other institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.